News
LTRN
3.220
+0.31%
0.010
Weekly Report: what happened at LTRN last week (0331-0404)?
Weekly Report · 04/07 11:30
Lantern Pharma Price Target Announced at $25.00/Share by Lake Street
Dow Jones · 04/02 13:16
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25
Benzinga · 04/02 13:06
Lantern Pharma initiated with a Buy at Lake Street
TipRanks · 04/02 12:47
Weekly Report: what happened at LTRN last week (0324-0328)?
Weekly Report · 03/31 11:43
Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges
TipRanks · 03/29 00:02
Lantern Pharma Advances AI-Driven Oncology Pipeline
TipRanks · 03/28 03:53
Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials
Seeking Alpha · 03/28 00:36
Lantern Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/27 21:00
Based on the provided financial report articles, I generated the title for the article: "LTRN's Financial Report: 2024 Annual Report and 2023 Comparative Analysis" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be a financial report for LTRN (company name) covering the year 2024 and providing a comparative analysis with 2023.
Press release · 03/27 20:58
Lantern Pharma GAAP EPS of -$0.54 misses by $0.03
Seeking Alpha · 03/27 20:48
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress
TipRanks · 03/27 20:35
Lantern Pharma Q4 2024 GAAP EPS $(0.54) Misses $(0.51) Estimate
Benzinga · 03/27 20:28
LANTERN PHARMA INC QTRLY EPS $-0.54
Reuters · 03/27 20:18
Lantern Pharma reports Q4 EPS (54c) vs (39c) last year
TipRanks · 03/27 20:06
*Lantern Pharma 4Q Loss/Shr 54c >LTRN
Dow Jones · 03/27 20:06
Press Release: Lantern Pharma Provides Business -2-
Dow Jones · 03/27 20:01
Press Release: Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
Dow Jones · 03/27 20:01
Earnings Scheduled For March 27, 2025
Benzinga · 03/27 08:32
Preview: Lantern Pharma's Earnings
Benzinga · 03/26 18:03
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
More
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.